Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosuvastatin - AstraZeneca

Drug Profile

Rosuvastatin - AstraZeneca

Alternative Names: Crestor; CRESTOR OD; Rosuvas; Rosuvastatin calcium; S 4522; ZD 4522

Latest Information Update: 11 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer AstraZeneca; Shionogi
  • Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
  • Discontinued Heart failure

Most Recent Events

  • 29 Jan 2019 AstraZeneca completes a phase III trial in Atherosclerosis in China (PO) (NCT02546323)
  • 03 Mar 2017 Yuhan Corporation plans a phase III trial for Hypertension and Hyperlipidaemia (Combination therapy) (NCT03067688)
  • 30 Nov 2016 AstraZeneca completes the extension study of the phase III HYDRA trial for Hypercholesterolaemia (In adolescents, In children) in Belgium, Canada, Denmark, Israel, Malaysia and Taiwan (NCT02434497)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top